Quarterly 13F snapshot: US-listed longs only, no performance figures — 13F data cannot support them.
Reported portfolio value by quarter (53 quarters reported)
$68.3M in Q2 2013 → $524M now. Hover for any quarter.
As reported for the quarter ended June 30, 2026. Activity is the change in share count since the prior quarter's filing.
| Holding | % of portfolio | Activity | Shares | Value |
|---|---|---|---|---|
| Revolution Medicines Inc | 20.1% | Trimmed 3.1% | 562,630 | $105M |
| SS SPDR S&P Biotech ETF | 5.9% | Trimmed 38% | 196,505 | $31.1M |
| Compass Pathways PLC | 5.4% | Trimmed 17% | 2,011,952 | $28.5M |
| Stereotaxis Inc | 4.5% | Unchanged | 13,680,554 | $23.5M |
| Nektar Therapeutics | 4.2% | Added 93% | 318,380 | $22.2M |
| Denali Therapeutics Inc | 3.6% | Added 132% | 739,014 | $19M |
| Ideaya Biosciences Inc | 3.5% | Added 4.3% | 497,240 | $18.5M |
| Atricure Inc | 3.2% | Unchanged | 597,431 | $16.7M |
| Xenon Pharmaceuticals Inc | 2.9% | Unchanged | 250,772 | $15.1M |
| Cytokinetics Inc | 2.8% | Trimmed 21% | 171,998 | $14.7M |
| Arcus Biosciences Inc | 2.6% | Trimmed 0.5% | 441,829 | $13.6M |
| Ascendis Pharma A/s | 2.5% | New | 48,469 | $12.9M |
| Neurocrine Biosciences Inc | 1.9% | Trimmed 18% | 57,769 | $9.74M |
| Axogen Inc | 1.8% | Trimmed 16% | 208,960 | $9.65M |
| Insulet Corp | 1.8% | Added 469% | 61,870 | $9.42M |
| Edgewise Therapeutics Inc | 1.8% | Added 102% | 226,819 | $9.22M |
| Bicara Therapeutics Inc | 1.6% | Trimmed 32% | 284,955 | $8.46M |
| IN Ishares Nasdaq Biotech Indx | 1.5% | Trimmed 31% | 42,595 | $8.1M |
| Syndax Pharmaceuticals Inc | 1.4% | Added 54% | 335,255 | $7.33M |
| Maplight Therapeutics Inc | 1.2% | Unchanged | 171,006 | $6.13M |
| Larimar Therapeutics Inc | 1.2% | Trimmed 1.0% | 2,008,164 | $6.12M |
| Century Therapeutics Inc | 1.1% | Trimmed 1.4% | 2,400,458 | $5.88M |
| Dexcom Inc | 1.1% | Unchanged | 86,279 | $5.81M |
| Immunovant Inc | 1.1% | Trimmed 0.7% | 149,524 | $5.76M |
| Inogen Inc | 1.0% | Unchanged | 845,179 | $5.45M |
| Tandem Diabetes Care Inc | 1.0% | Unchanged | 355,208 | $5.36M |
| Alkermes PLC | 1.0% | Trimmed 27% | 101,266 | $5.31M |
| Stoke Therapeutics Inc | 0.8% | Unchanged | 130,875 | $4.28M |
| Allogene Therapeutics Inc | 0.8% | Added 46% | 2,000,000 | $4.16M |
| Biocryst Pharmaceuticals Inc | 0.8% | Trimmed 7.0% | 400,248 | $4M |
| LB Lakefront Biotherapeutics Nv | 0.7% | Unchanged | 130,175 | $3.9M |
| Orthopediatrics Corp | 0.7% | Added 98% | 189,130 | $3.62M |
| Cybin Inc | 0.6% | Added 3.2% | 514,061 | $3.4M |
| Rapport Therapeutics Inc | 0.6% | Unchanged | 75,000 | $3.13M |
| Kymera Therapeutics Inc | 0.6% | New | 27,000 | $3.1M |
| Proqr Therapeutics Nv | 0.5% | Trimmed 2.4% | 1,530,361 | $2.85M |
| Neurogene Inc | 0.5% | Added 57% | 89,032 | $2.8M |
| AN Adlai Nortye Ltd | 0.5% | New | 239,553 | $2.75M |
| Procept Biorobotics Corp | 0.5% | Unchanged | 120,000 | $2.71M |
| Aquestive Therapeutics Inc | 0.5% | Added 75% | 645,915 | $2.69M |
| Celldex Therapeutics Inc | 0.5% | Unchanged | 68,518 | $2.55M |
| Structure Therapeutics Inc | 0.5% | Unchanged | 46,500 | $2.5M |
| Align Technology Inc | 0.5% | Trimmed 6.7% | 14,000 | $2.36M |
| Viking Therapeutics Inc | 0.4% | Unchanged | 59,516 | $2.32M |
| Nervgen Pharma Corp | 0.4% | New | 1,050,000 | $2.16M |
| Biohaven Ltd | 0.4% | Trimmed 84% | 137,593 | $2.05M |
| Maze Therapeutics Inc | 0.4% | Added 86% | 65,000 | $1.94M |
| Alector Inc | 0.3% | Unchanged | 908,351 | $1.83M |
| Lexeo Therapeutics Inc | 0.3% | Unchanged | 377,059 | $1.76M |
| Profound Medical Corp | 0.3% | Trimmed 1.0% | 260,360 | $1.73M |
| Atrium Therapeutics Inc | 0.3% | New | 128,000 | $1.72M |
| Annexon Inc | 0.3% | Added 153% | 297,812 | $1.7M |
| Cytomx Therapeutics Inc | 0.3% | Added 91% | 438,407 | $1.64M |
| Ultragenyx Pharmaceutical Inc | 0.3% | Trimmed 23% | 47,100 | $1.57M |
| Eupraxia Pharmaceuticals Inc | 0.3% | New | 225,600 | $1.49M |
| Design Therapeutics Inc | 0.3% | New | 102,600 | $1.48M |
| Fate Therapeutics Inc | 0.3% | Trimmed 4.5% | 525,000 | $1.42M |
| Mediwound Ltd | 0.3% | Unchanged | 94,405 | $1.39M |
| Kura Oncology Inc | 0.3% | Trimmed 49% | 120,568 | $1.32M |
| Ars Pharmaceuticals Inc | 0.3% | Added 18% | 164,285 | $1.32M |
Showing top 60 of 88 positions.
What changed each quarter, from the filings' own share counts. Largest moves first; most recent 8 quarters.
quarter ended June 30, 2026 · filed August 14, 2026
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| DO Day One Biopharmaceuticals I | Exited | −978,463 | −$21M | — |
| SS SPDR S&P Biotech ETF | Trimmed | −122,000 | −$19.3M | 5.9% |
| Ascendis Pharma A/s | New | +48,469 | +$12.9M | 2.5% |
| Denali Therapeutics Inc | Added | +420,514 | +$10.8M | 3.6% |
| Nektar Therapeutics | Added | +153,202 | +$10.7M | 4.2% |
| Biohaven Ltd | Trimmed | −708,142 | −$10.5M | 0.4% |
| Mbx Biosciences Inc | Trimmed | −163,656 | −$9.03M | 0.1% |
| Insulet Corp | Added | +51,000 | +$7.76M | 1.8% |
| Ascendis Pharma A/s | Exited | −4,000,000 | −$5.92M | — |
| Compass Pathways PLC | Trimmed | −406,930 | −$5.76M | 5.4% |
Showing the 10 largest of 72 changes.
quarter ended March 31, 2026 · filed May 15, 2026
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| Cytokinetics Inc | Trimmed | −153,500 | −$10.1M | 3.3% |
| Compass Pathways PLC | Added | +1,607,836 | +$8.89M | 3.0% |
| Axogen Inc | Trimmed | −226,866 | −$7.52M | 1.9% |
| Nektar Therapeutics | Added | +90,180 | +$6.49M | 2.7% |
| Larimar Therapeutics Inc | Added | +1,090,000 | +$4.91M | 2.1% |
| Astria Therapeutics Inc | Exited | −304,775 | −$3.99M | — |
| Bicara Therapeutics Inc | Added | +160,150 | +$3.19M | 1.9% |
| Revolution Medicines Inc | Trimmed | −23,836 | −$2.32M | 12.8% |
| SS SPDR S&P Biotech ETF | Trimmed | −18,000 | −$2.3M | 9.3% |
| Xenon Pharmaceuticals Inc | Trimmed | −37,167 | −$2.16M | 3.3% |
Showing the 10 largest of 63 changes.
quarter ended December 31, 2025 · filed February 17, 2026
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| MB Merus Bv | Exited | −220,451 | −$20.8M | — |
| Axogen Inc | Trimmed | −265,456 | −$8.69M | 3.6% |
| Biohaven Ltd | Added | +720,000 | +$8.13M | 2.5% |
| SS SPDR S&P Biotech ETF | Trimmed | −65,000 | −$7.93M | 9.5% |
| IN Ishares Nasdaq Biotech Indx | Trimmed | −34,405 | −$5.81M | 2.7% |
| Syndax Pharmaceuticals Inc | Trimmed | −222,847 | −$4.68M | 1.4% |
| Arcus Biosciences Inc | Trimmed | −196,297 | −$4.68M | 2.4% |
| Revolution Medicines Inc | Trimmed | −52,662 | −$4.19M | 11.2% |
| Procept Biorobotics Corp | New | +120,000 | +$3.78M | 0.9% |
| Cybin Inc | New | +455,018 | +$3.72M | 0.9% |
Showing the 10 largest of 67 changes.
quarter ended September 30, 2025 · filed November 14, 2025
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| Blueprint Medicines Corp | Exited | −168,763 | −$21.6M | — |
| MB Merus Bv | Trimmed | −178,353 | −$16.8M | 5.1% |
| Mineralys Therapeutics Inc | Trimmed | −288,033 | −$10.9M | 0.8% |
| Ascendis Pharma A/s | Trimmed | −39,500 | −$7.85M | 1.6% |
| Stoke Therapeutics Inc | Trimmed | −332,181 | −$7.81M | 1.0% |
| Urogen Pharma Ltd | Trimmed | −322,000 | −$6.42M | 0.1% |
| Soleno Therapeutics Inc | New | +53,000 | +$3.58M | 0.9% |
| Nektar Therapeutics | Added | +44,998 | +$2.56M | 0.8% |
| Rapport Therapeutics Inc | New | +75,000 | +$2.23M | 0.6% |
| Ideaya Biosciences Inc | Trimmed | −79,167 | −$2.15M | 3.6% |
Showing the 10 largest of 49 changes.
quarter ended June 30, 2025 · filed August 14, 2025
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| MB Merus Bv | Trimmed | −63,000 | −$3.31M | 5.8% |
| Biocryst Pharmaceuticals Inc | Trimmed | −340,000 | −$3.05M | 0.5% |
| 2seventy Bio Inc | Exited | −429,252 | −$2.12M | — |
| Blueprint Medicines Corp | Added | +16,500 | +$2.11M | 6.0% |
| Urogen Pharma Ltd | Trimmed | −143,000 | −$1.96M | 1.3% |
| Kalvista Pharmaceuticals Inc | Trimmed | −170,602 | −$1.93M | 1.8% |
| Regulus Therapeutics Inc | Exited | −847,176 | −$1.48M | — |
| Compass Therapeutics Inc | New | +526,660 | +$1.37M | 0.4% |
| Ascendis Pharma A/s | Trimmed | −7,721 | −$1.33M | 3.5% |
| Ars Pharmaceuticals Inc | Exited | −95,290 | −$1.2M | — |
Showing the 10 largest of 56 changes.
quarter ended March 31, 2025 · filed May 15, 2025
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| Ascendis Pharma A/s | Trimmed | −22,957 | −$3.58M | 3.6% |
| Axogen Inc | Trimmed | −166,100 | −$3.07M | 3.6% |
| Arcus Biosciences Inc | Added | +370,909 | +$2.91M | 1.4% |
| Mineralys Therapeutics Inc | Added | +162,700 | +$2.58M | 1.4% |
| Stoke Therapeutics Inc | Added | +272,901 | +$1.81M | 0.8% |
| Inogen Inc | Added | +249,275 | +$1.78M | 0.9% |
| Denali Therapeutics Inc | New | +127,900 | +$1.74M | 0.5% |
| Atricure Inc | Trimmed | −49,400 | −$1.59M | 5.4% |
| Ideaya Biosciences Inc | Added | +90,503 | +$1.48M | 2.7% |
| Bicara Therapeutics Inc | Added | +106,501 | +$1.39M | 0.8% |
Showing the 10 largest of 54 changes.
quarter ended December 31, 2024 · filed February 14, 2025
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| Revolution Medicines Inc | Added | +113,182 | +$4.95M | 7.0% |
| Tela Bio Inc | New | +1,441,029 | +$4.35M | 1.1% |
| Viking Therapeutics Inc | Trimmed | −61,100 | −$2.46M | 0.7% |
| Blueprint Medicines Corp | Added | +28,000 | +$2.44M | 3.3% |
| Ascendis Pharma A/s | Added | +13,783 | +$1.9M | 3.6% |
| Bicara Therapeutics Inc | New | +105,500 | +$1.84M | 0.5% |
| PT Proqr Therapeutics N V | Added | +661,979 | +$1.75M | 1.1% |
| Merus N V | Added | +39,231 | +$1.65M | 4.8% |
| Aquestive Therapeutics Inc | Trimmed | −462,561 | −$1.65M | 0.1% |
| Acelyrin Inc | Trimmed | −514,905 | −$1.62M | 0.1% |
Showing the 10 largest of 63 changes.
quarter ended September 30, 2024 · filed November 14, 2024
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| Morphic Holding Inc | Exited | −231,748 | −$7.9M | — |
| SS SPDR S&P Biotech ETF | Trimmed | −43,500 | −$4.3M | 9.4% |
| Viking Therapeutics Inc | Trimmed | −63,501 | −$4.02M | 1.9% |
| Syndax Pharmaceuticals Inc | Trimmed | −130,372 | −$2.51M | 2.4% |
| Lexeo Therapeutics Inc | New | +250,583 | +$2.27M | 0.5% |
| 2seventy Bio Inc | Trimmed | −420,680 | −$1.99M | 0.7% |
| Edgewise Therapeutics Inc | Trimmed | −62,291 | −$1.66M | 1.4% |
| Biohaven Ltd | Trimmed | −31,600 | −$1.58M | 2.2% |
| Blueprint Medicines Corp | Added | +17,000 | +$1.57M | 2.7% |
| Ideaya Biosciences Inc | Added | +49,197 | +$1.56M | 3.5% |
Showing the 10 largest of 56 changes.
Loading...
